Nutra Pharma Announces Publication of Research on Treatment for Multiple SclerosisBOCA RATON, Fla.--(BUSINESS WIRE)--Mar 22, 2007 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its drug discovery division, ReceptoPharm, has received notification of acceptance of its paper for publication in the Critical Reviews in Immunology special conference issue.
The article, entitled "Alpha-Cobratoxin as a possible therapy for Multiple Sclerosis; a review of the literature leading to its development for this application," discusses the background and reasoning behind ReceptoPharm's research on its treatment for Multiple Sclerosis (MS). The Company has completed Phase I studies and is preparing to begin its Phase II human clinical trials.
"We are honored to have our paper accepted for publication in such a well respected journal," commented Paul Reid, CEO of ReceptoPharm, Inc. "Alpha-Cobratoxin could play an important role in treating Multiple Sclerosis and we believe it is important to disseminate our research throughout the scientific community," he added.
Recently, ReceptoPharm announced it received a letter of intent to create a joint venture in China aimed at developing the Company's antiviral drug, RPI-MN, for the Chinese market. RPI-MN is ReceptoPharm's lead drug candidate being researched for the treatment of HIV/AIDS and other viral disorders.
About Critical Reviews in Immunology
The great advances in immunology in recent years make this field one of the most rapidly growing in biological sciences. Critical Reviews(TM) in Immunology presents a balanced overview of contemporary immunology and melds together molecular immunology and immunobiology. The Journal is published six times each year.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The publication of the ReceptoPharm article should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Nutra Pharma Corp.
David Isserman, 877-895-5647
Posted: March 2007